Inorganic arsenic (iAs) is a recognized carcinogen and toxicant \[National Research Council (NRC) 2001; World Health Organization (WHO) International Programme on Chemical Safety 2001\] that is commonly present in groundwater. Causal relationships between long-term elevated iAs exposure and cancer of the skin, lung, and bladder have been accepted \[International Agency for Research on Cancer (IARC) 2004, 2009\]. Although certain populations, such as in Bangladesh, West Bengal, Taiwan, parts of China, Argentina, and northern Chile, have been exposed to very high concentrations of iAs in drinking water (several hundred micrograms per liter) (IARC 2004), there is widespread exposure worldwide to low concentrations of iAs, in the range of 5--50 μg/L in drinking water and 5--100 μg/kg in food, especially cereals and vegetables ([@r14]; [@r36]). The NRC risk assessment (NRC 2001) indicates a comparatively high cancer risk even at concentrations as low as 10 μg/L in drinking water; however, these risk estimates, as well as current WHO, European Union, and U.S. drinking water guidelines ([@r13]; U.S. Environmental Protection Agency 2001; WHO 2011), are based on linear extrapolation of cancer risks at low doses in studies with relatively high iAs exposure, mainly in Taiwan ([@r6], [@r5]; [@r9]; [@r46]; [@r55]). Concerns have been raised about the validity of such extrapolation, in part because accepted modes of action, which do not include direct DNA mutations, would be expected to result in a threshold dose response ([@r40]).

The effects of elevated iAs exposure on the risk of nonmelanoma skin cancer, mainly squamous cell carcinoma and basal cell carcinoma (BCC), have been recognized in highly exposed populations for some time ([@r4]; [@r7]; [@r6], [@r8]; [@r16]; [@r17]; [@r19]; [@r27]; [@r44]; [@r45]; [@r46]). However, there is little direct evidence of skin cancer risk resulting from exposure to drinking water containing \< 100 μg/L iAs ([@r2]; [@r25]).

The Arsenic Health Risk Assessment and Molecular Epidemiology (ASHRAM) study aimed to quantify the risks of several cancer types in relation to long-term low-level iAs exposure via drinking water in Hungary, Romania, and Slovakia. The associations with BCC of the skin are presented here.

Materials and Methods
=====================

For the ASHRAM study, the study areas included districts in central Slovakia where drinking water is derived from a cracked hard rock aquifer, as well as districts in eastern Hungary and western Romania located on the Great Hungarian Plain, an alluvial basin that straddles the Hungarian--Romanian border. More precisely, the study included the Hungarian counties Bács-Kiskun, Békés, Csongrád, and Jász-Nagykun-Szolnok; the Romanian counties Arad and Bihor; and the Slovakian districts Nitra, Nove Zamky, and Levice within Nitra County, and Banska Bystrica, Brezno, Ziar nad Hronom, and Zarnovica within Banska Bystrica County (total population \~ 4.5 million). Routine monitoring of sources indicated that approximately 1,100,000 individuals had used water with \> 10 μg iAs/L, but generally \< 100 μg/L, at some point during the past 30 years ([@r18]). The study was conducted with individuals who provided written informed consent and were part of the majority Caucasian population, excluding the minority Roma population. Ethical approval was obtained from the Ethical Committee of the National Health Research Council and the Regional Ethical Committee of the Szentgyörgyi Albert University of Szeged (Hungary), from local hospitals and public health departments (Romania), and from ethical committees established in hospitals and state health institutes (Slovakia) included in the study.

In the absence of population registers, we worked with public health agencies to identify incident cases of BCC \[*International Classification of Diseases, 10th Revision* (ICD-10) code C44 (WHO 1993)\] and controls diagnosed among those 30--79 years of age in the same areas. Recruitment of cases and controls was carried out over 21 months (January 2003--September 2004). Because BCC cases may be diagnosed in primary or private care, a case--control study of BCC based on cases identified only at hospitals may provide an incomplete ascertainment. However, we determined that pathologists at public hospitals were responsible for histological confirmation of all BCC cases in the study areas. Therefore, identification of BCC cases entailed a system whereby each pathologist would inform the local study coordinator every time a new case of BCC was diagnosed by histology, so that the identification of BCC cases did not require cooperation by the large network of hospital- and community-based clinicians responsible for diagnosing cases.

Hospital-based case--control studies have been criticized because of the potential for selection bias resulting from recruitment of controls from a population systematically different from the source population for cases. In addition, selection bias would result if recruitment of cases and controls differed by geographical area that may be associated with degree of potential iAs exposure. Therefore, to ensure equivalent geographic coverage of populations for sampling both cases and controls, we recruited controls from all 24 hospitals in the study area, including six smaller hospitals in more peripheral areas that did not have pathology departments involved in the histological confirmation of BCC cases. All of the targeted hospitals agreed to participate in the study. Controls were general surgery in-patients (appendicitis, abdominal hernia, duodenal ulcer, or cholelithiasis, with ICD-10 diagnostic codes K35--K37, K40--K46, K26, K80) and orthopedic and trauma patients (fractures, with ICD-10 diagnostic codes SO2, S12, S22, S32, S42, S52, S62, S72, S82, S92, TO2, TO8, T10, T12) 30--79 years of age. We recruited controls diagnosed with a variety of conditions from two distinct hospital departments to reduce the possibility that geographic variation in patterns of diagnosis and clinical practice might lead to systematic differences between control and base population distributions.

Controls served as the comparison group for analyses of other cancers (bladder and kidney) in addition to BCC. Therefore, controls were frequency matched to all potential cancer cases by sex, 5-year age band, and residence in the same county/region of the study area. Cases and controls were included if they had resided in the study area for at least 1 year during their lifetime. Because a complete roster of all eligible controls admitted to all the hospitals in the region was not available, recruitment of controls was proportional to the expected number of potential controls at each hospital indicated by past data. Control selection continued until the target number of interviews was completed. This procedure led to a systematic rotation between hospitals and control diagnoses and therefore constructed a series of controls that was similar to that of the cases for age group, sex, and county of residence while minimizing the opportunity for systematic error in control selection ([@r28]). Clinicians and pathologists were blind to the exposure status of cases and controls.

A face-to-face interview was conducted with each participant to obtain a detailed residential history focused on identification of drinking water sources at home and information on potential confounders, including sunlight exposure, skin characteristics, educational attainment, sex, age, smoking history, height, and weight reported for age 20, before their illnesses. Participants also completed interviewer-administered food frequency questionnaires (Hough 2010). Interviewers from the three countries were staff of public health institutes who had attended training workshops to ensure consistent approach to data collection following the study protocol. Interviewers asked participants about the hours per day spent in the sun at different ages over their lifetime, as well as self-reported skin complexion, eye color, skin reaction to midday sun, and history of sunburns and red skin from sun exposure. From the questionnaire responses, four indices of exposure to sunlight were generated: peak exposure was defined as the highest annual number of hours of exposure to the sun; cumulative lifetime exposure, as the lifetime number of hours of exposure to the sun; skin sensitivity to burns, as an index based on the intensity of the cutaneous reaction to 1-hr midday sun exposure of the upper trunk; and skin complexion, as the self-reported complexion of the skin as light, medium, or dark.

*Exposure model.* For each individual, the concentrations of iAs in drinking water at addresses over their lifetime were derived from measurements at the time of the study and historical data provided by national water authorities as described in detail elsewhere ([@r18]). When historical data were unavailable, past concentrations of iAs in village and private wells were assumed to be the same as currently measured concentrations in water samples from the same wells. Address and water source data were collected on up to nine different residences over each person's lifetime, and, at minimum, we attempted to measure iAs in current samples obtained from the first, last, and longest reported addresses. All water samples were analyzed by the same laboratory in Cluj-Napoca, Romania, using hydride generation/atomic absorption spectrometry accompanied by strict quality assurance and quality control (QA/QC) procedures. Based on sample measurements and historical information, concentrations of iAs in residential supplies were assigned for 80.09% of case and 80.07% of control lifetime years. Based on these lifetime concentration profiles and individual fluid intakes, three exposure indices were constructed: the peak daily dose rate (micrograms iAs per day) at the participant's residence with the highest water iAs concentration, the time-weighted average concentration (micrograms iAs per liter) over the lifetime of each individual, and the lifetime cumulative dose (grams iAs) ([@r18]).

Each participant was asked to provide an early morning urine sample. The samples were placed in a freezer at --20°C within 15 min of collection to limit influence on the chemical species of iAs in urine. Urinary metabolites of iAs, methylarsonic acid \[MA, MA(V) unless otherwise noted\] and dimethylarsinic acid \[DMA, DMA(V) unless otherwise noted\] were measured with high-performance liquid chromatography with inductively coupled plasma/mass spectrometry ([@r29]). Total urinary metabolites were computed as the sum of iAs, MA, and DMA. Concentrations of iAs in urine were adjusted to the average specific gravity in the population. Details on concentrations of iAs in water and urine samples and their relevance for exposure assessment are available elsewhere ([@r29]).

*Statistical analyses.* Data were analyzed in STATA (version 10; [@r41]) using separate multivariable logistic regression models for each iAs exposure index that included variables representing potential confounders defined *a priori*: several indices of sun exposure, age, sex, number of years of education (proxy for socioeconomic status), and county. Preliminary analyses identified skin response to 1-hr midday sun and skin complexion as the sunlight exposure indices most strongly predicting BCC risk in this population, so these were included in models including exposure. This population was part of a larger study of skin, bladder, and kidney cancers with a common referent population, and the targets were for similar numbers of controls and all cancers per county. The relative numbers of the different cancers varied geographically, so the BCC case:control ratio varied arbitrarily by county (and country). This geographic matching was accounted for in analyses by using logistic regression conditional on county (STATA command xtlogit, fe), which also controlled for variation across counties (clustering) of unmeasured risk factors.

Quintiles of exposure for the controls were defined for each exposure index and used for classifying cases and controls to explore the shape of the relationships. The trend across quintile was assessed by fitting a linear term for exposure quintile. To evaluate possible departure from linearity, likelihood ratio tests were used to compare the fit of models with exposure quintile as a categorical variable versus quintile as a linear term.

Each index was also treated as a continuous variable in regression models to estimate the overall slope of the exposure response, with skin cancer relative risk expressed as odds ratios (ORs) for unit changes in each exposure: 10-μg/L increase in lifetime average iAs concentration, 10-μg/day increase in peak iAs daily dose rate, and increase of 0.274 g in cumulative iAs dose derived from 50 years of drinking 1.5 L water per day containing 10 μg/L iAs.

We conducted analyses adjusted for smoking and body mass index (BMI), but including these covariates did not alter the magnitude of associations very much. Because neither smoking nor BMI is a likely confounder in a study of BCC, we did not include them in the reported analyses.

Because other iAs exposure routes, particularly diet, may be significant when concentrations of iAs in drinking water are low ([@r29]), we performed analyses that excluded those with a sum of iAs metabolites in urine \< 2.5 μg/L (in line with [@r29]). Because of potential interest in exposure to \< 50 μg/L of iAs in drinking water, a further sensitivity analysis was carried out after excluding participants with lifetime average iAs concentrations above the 90th percentile of lifetime average iAs concentrations (40.7 μg/L), within the group with a sum of iAs metabolites ≥ 2.5 μg/L.

The principal metabolic data were *a priori* defined as the percentage of MA and DMA (in relation to total concentration of iAs metabolites) in the urine (MA% and DMA%, respectively). Stratified analyses were conducted to evaluate effect modification by methylation efficiency on the association between BCC and iAs exposure. Two dichotomous variables representing DMA% and MA% below and above the median were modeled along with multiplicative interaction terms between each dichotomous variable and the iAs exposure indices (as continuous variables). Modification of the association between iAs and BCC by DMA and MA was evaluated based on Wald tests ([@r10]).

Results
=======

Of the 1,406 patients invited, 1,197 (85.1%) consented to participate in the study (81.6% among cases, 90.0% among controls). Later, 96 potential cases were excluded because they had skin cancer other than BCC, 34 because they did not have histological confirmation, and 4 for other reasons. Thus, in total, the study included 1,069 valid participants, of whom 529 were BCC cases and 540 were controls. Consistent with expectations for BCC, a cancer known to be caused by sun exposure, cases had a higher prevalence of skin burns in response to sun exposure than did controls, as well as a higher prevalence of light skin complexion ([Table 1](#t1){ref-type="table"}).

###### 

Study population and characteristics \[n (%)\].

  Characteristic                     Cases   Controls      Total (n)                    
  ---------------------------------- ------- ------------- ----------- ------------- -- ------------
  Country/county                                                                        
  Hungary, total                             160 (30.3)                249 (46.1)       409
  Bács-Kiskun                                90 (17.1)                 101 (18.7)       191
  Békés                                      23 (4.4)                  23 (4.3)         46
  Csongrád                                   24 (4.5)                  61 (11.3)        85
  Jász-Nagykun-Szolnok                       23 (4.4)                  64 (11.9)        87
  Romania, total                             158 (29.9)                156 (28.9)       314
  Arad                                       90 (17.0)                 100 (18.5)       190
  Bihor                                      68 (12.9)                 56 (10.4)        124
  Slovakia, total                            211 (39.9)                135 (25.0)       346
  Banska Bystrica                            92 (17.4)                 70 (13.0)        162
  Nitra                                      119 (22.5)                65 (12.0)        184
  Age (years)                                                                           
  \< 45                                      20 (3.9)                  55 (10.3)        75
  45--49                                     33 (6.4)                  47 (8.8)         80
  50--54                                     31 (6.0)                  61 (11.4)        92
  55--59                                     63 (12.1)                 77 (14.5)        140
  60--64                                     65 (12.5)                 76 (14.3)        141
  65--69                                     106 (20.4)                83 (15.6)        189
  70--74                                     113 (21.7)                78 (14.7)        191
  75--79                                     89 (17.1)                 56 (10.5)        145
  Missing                                    9                         7                16
  Sex                                                                                   
  Male                                       237 (44.8)                278 (51.5)       515
  Female                                     292 (55.2)                262 (48.5)       554
  Skin response to 1-hr midday sun                                                      
  Blistered                                  71 (13.7)                 59 (11.1)        130
  Sunburned                                  114 (22.0)                83 (15.6)        197
  Mild burn                                  169 (32.6)                161 (30.3)       330
  Tan                                        157 (30.3)                206 (38.8)       363
  No change                                  7 (1.4)                   22 (4.1)         29
  Missing                                    11                        9                20
  Skin complexion                                                                       
  Light                                      271 (51.3)                222 (41.2)       493
  Medium                                     241 (45.6)                258 (47.9)       499
  Dark                                       16 (3.0)                  59 (11.0)        75
  Missing                                    1                         1                2
  Total                                      529 (100.0)               540 (100.0)      1,069
  Years of education (mean ± SD)             10.1 ± 4.1                10.2 ± 3.7       10.1 ± 3.9

The lifetime average iAs concentration in residential drinking water had a median value of 1.2 μg/L, with an interquartile range (IQR) of 0.7--13.8 μg/L. It is evident from the distribution of lifetime average iAs concentration (quintiles of controls) shown in [Table 2](#t2){ref-type="table"} that much of the population (first three quintiles) had exposure \< 7 μg/L.

###### 

Results of logistic regression models of iAs exposure by quintile and BCC in the ASHRAM study population \[OR (95% confidence interval)\].

  Arsenic exposure index/quintile (range of exposure in controls)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Adjusteda   Additionally adjustedb   Trend test (p-value)                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------- ------------------------ ---------------------- ------------------- -- -------
  Lifetime average iAs concentration (μg/L)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             0.001
  0.00--0.68                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     1.00                                            1.00                   
  0.68--0.98                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     1.27 (0.82, 1.97)                               1.39 (0.89, 2.19)      
  0.98--7.00                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     1.02 (0.67, 1.56)                               1.20 (0.77, 1.88)      
  7.10--19.43                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1.63 (0.93, 2.85)                               1.73 (0.97, 3.11)      
  19.54--167.29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  2.81 (1.62, 4.87)                               3.03 (1.70, 5.41)      
  Peak daily iAs dose rate (μg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     0.001
  0.00--0.73                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     1.00                                            1.00                   
  0.73--1.48                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     0.93 (0.62, 1.39)                               0.91 (0.59, 1.39)      
  1.48--9.09                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     1.29 (0.86, 1.95)                               1.55 (1.00, 2.41)      
  9.09--32.23                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1.78 (1.05, 3.02)                               1.76 (1.01, 3.07)      
  32.23--242.14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  2.31 (1.32, 4.03)                               2.50 (1.39, 4.49)      
  Cumulative iAs dose (g)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               0.001
  0.00--0.01                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     1.00                                            1.00                   
  0.01--0.03                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     1.02 (0.68, 1.52)                               1.09 (0.72, 1.67)      
  0.03--0.13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     1.19 (0.78, 1.81)                               1.46 (0.93, 2.27)      
  0.13--0.55                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     1.73 (1.02, 2.91)                               1.76 (1.02, 3.04)      
  0.55--4.46                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     2.45 (1.39, 4.32)                               2.63 (1.45, 4.78)      
  Relative risks of BCC were estimated as ORs comparing risk of cancer in a quantile with the quintile of lowest exposure. Range of iAs exposure within each quintile is expressed in the unit of measure specific for each exposure index. aAdjusted for county, age, and sex, based on n = 1,022 for peak dose rate, n = 1,025 for lifetime average concentration, and n = 1,011 for cumulative dose. bAdditionally adjusted for education, skin response to 1-hr midday sun, and skin complexion, based on n = 989 for peak dose rate, n = 992 for lifetime average concentration, n = 979 for cumulative dose.                                                                                      

*Arsenic and risk of BCC.* In general, ORs increased with increasing iAs exposure categories, and all trend tests for the linear relationship between the categorical exposure variable and BCC were statistically significant ([Table 2](#t2){ref-type="table"}). Comparison by likelihood ratio tests of models with quintile of exposure as a categorical variable and a linear variable did not provide evidence of nonlinearity in the exposure--response relationship. Subsequent analyses were conducted based on the assumption that the dose--response relation between iAs exposure indexes and BCC can be summarized appropriately using simple continuous exposure variables.

All three iAs exposure indices were significantly associated with BCC when adjusted for county, age, and sex, and ORs were comparable after further adjustment for education, skin response to 1-hr midday sun, and skin complexion ([Table 2](#t2){ref-type="table"}). Associations were also significant when exposures were modeled as continuous variables, with similar effect estimates after excluding individuals whose sum of iAs metabolites in current urine was \< 2.5 μg/L ([Table 3](#t3){ref-type="table"}). Associations were increased after further excluding participants with lifetime average iAs water concentration above the 90th percentile (41 μg/L).

###### 

Logistic regression models of iAs exposure and BCC in the ASHRAM study population \[OR (95% confidence interval)\].

  Arsenic exposure index                                                                                                                                                                                                                                                                                                                                                                                              All observations (n = 1,069)   Observations with metabolites ≥ 2.5 μg/L (n = 856)   Observations with metabolites ≥ 2.5 μg/L and lifetime average As \< 40.7 μg/L (n = 736)                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------ ---------------------------------------------------- ----------------------------------------------------------------------------------------- ------------------- -- -------------------
  Lifetime average As concentration                                                                                                                                                                                                                                                                                                                                                                                                                  1.18 (1.08, 1.28)                                                                                                                              1.15 (1.06, 1.26)      1.41 (1.14, 1.76)
  Peak daily As dose rate                                                                                                                                                                                                                                                                                                                                                                                                                            1.13 (1.07, 1.20)                                                                                                                              1.12 (1.06, 1.19)      1.18 (1.04, 1.33)
  Cumulative As dose                                                                                                                                                                                                                                                                                                                                                                                                                                 1.10 (1.01, 1.19)                                                                                                                              1.08 (1.00, 1.18)      1.16 (0.95, 1.41)
  Relative risks of BCC were estimated as ORs for unit changes in exposure: a 10-μg/L increase in lifetime average iAs concentration, a 10‑μg/day increase in peak iAs daily dose rate, or an increase in cumulative iAs dose derived from 50 years of drinking 1.5 L water/day containing 10 μg/L iAs. All models adjusted for county, age, sex, education, skin response to 1-hr midday sun, and skin complexion.                                                                                                                                                                                                        

*Effect modification by iAs metabolism.* Median DMA% was 76.6% (median concentration, 4.0 μg/L; IQR, 2.1--9.7 μg/L), and median MA% was 15.8% (median concentration, 0.8 μg/L IQR, 0.4--2.1 μg/L; [Table 4](#t4){ref-type="table"}). Among participants with sum of iAs metabolites ≥ 2.5 μg/L, associations with all three indices of iAs exposure were stronger in participants with low DMA% or high MA%, with little or no evidence of associations among participants with high DMA% or low MA%. Similar results were obtained for the overall group (including those with metabolites \< 2.5 μg/L; data not shown).

###### 

Associations between BCC and As according to urine iAs metabolite levels among participants with sum of iAs metabolites ≥ 2.5 μg/L (n = 856).

  Arsenic exposure index                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               \< Mediana \[ORb (95% CI)\]   ≥ Mediana \[ORb (95% CI)\]   p-Valuec                          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------- ---------------------------- ---------- ------------------- -- -------
  Lifetime average concentration                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  DMA%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1.21 (1.10, 1.35)                       1.03 (0.92, 1.15)      0.017
  MA%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                1.04 (0.94, 1.17)                       1.21 (1.09, 1.35)      0.032
  Peak daily As dose rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  DMA%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1.14 (1.06, 1.23)                       1.05 (0.96, 1.15)      0.098
  MA%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                1.05 (0.97, 1.15)                       1.15 (1.06, 1.23)      0.095
  Cumulative As dose                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  DMA%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1.11 (1.01, 1.22)                       0.99 (0.88, 1.12)      0.119
  MA%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                1.02 (0.91, 1.14)                       1.10 (1.00, 1.22)      0.222
  Relative risks of BCC were estimated as ORs for unit changes in exposure: a 10 μg/L increase in lifetime average iAs concentration, a 10-μg/day increase in peak iAs daily dose rate, or an increase in cumulative iAs dose derived from 50 years of drinking 1.5 L water/day containing 10 μg/L iAs. aMedian DMA%, 76.6%; median MA%, 15.8%. bThese ORs are stratum specific because they estimate effect of iAs on cancer as a linear effect, separately by level of metabolite, for both DMA% and MA%, and controlled for potential confounders county, age, sex, education, skin response to 1-hr midday sun, and skin complexion. cp-Values for multiplicative interaction terms between dichotomous variables for DMA% or MA% and continuous variables for iAs exposure indexes (Wald test).                                                                                                

Discussion
==========

The ASHRAM study demonstrates strong evidence of an association between long-term low-level exposure to iAs in drinking water and BCC. To our knowledge this is the first report of a significant association between BCC and average drinking water iAs concentrations \< 50 μg/L---concentrations common in many countries and affecting many millions of people. In addition, individuals with less efficient iAs methylation to DMA appeared to be at higher risk of BCC in association with iAs exposure. The relative risk of BCC was elevated in relation to all three indices of long-term iAs exposure (lifetime average concentration, cumulative and peak dose), and the relationship remained significant after controlling for potential confounders, including indices of ultraviolet exposure.

Hospital-based case--control studies with a specific disease outcome have as their secondary population base a cohort of people who theoretically would be admitted to that hospital had they contracted the outcome disease ([@r31]; [@r50], [@r51]). Selection bias could arise from systematic differences in selection of cases and controls. Difference in unmeasured confounders between countries and counties was addressed in part by including county indicator variables in all models. Geographic variation in case versus control ascertainment could potentially lead to biased estimates of iAs effect if associated with geographic variation in iAs exposure. To optimize case ascertainment, we collaborated with all pathologists qualified to make diagnoses of BCC in the study areas. To minimize the potential for selection bias associated with control selection, we included all health care facilities where control diagnoses were produced, whether or not BCC cases were diagnosed at the facility. In addition, we identified several potentially suitable control diagnoses, including both general surgery and trauma. Overall, we believe that we achieved similar countywide coverage for cases and controls and minimized potential bias due to geographic differences in ascertainment related to iAs exposure.

A validation study was conducted to compare the proportion of controls from larger cities and towns with the proportion of base population from the same towns. Together, larger cities and towns constitute a more urban "subcounty area" than the smaller towns and villages that account for the remaining portions of the study counties. From census figures in the three countries ([@r21]; National Institute of Statistics, Romania 2011a, 2011b; Statistical Office of the Slovak Republic 2011), we identified base population counts for geographic areas at subcounty level (3,503,581) and in the larger cities and towns (1,238,984). The proportion of the base population in the larger cities and towns (35.4%) was comparable to the proportion of controls from the same areas (187 of 538 total controls, 34.8%), which suggests that the control group is representative of the base population. In addition, response rates were high and similar between cases and controls. However, iAs exposures were higher in the rural areas than in the urban subcounty areas, with average lifetime iAs concentrations of 2.9 μg/L and 0.9 μg/L, respectively, and some residual bias cannot be ruled out completely.

Analysis of total concentrations of iAs in drinking water in the present study was based on established analytical chemistry techniques, and the QA/QC program demonstrated that measured concentrations of iAs were within acceptable margins of error. Thus, analytical data were suitable for estimating current exposure from drinking water for all participants. Historic data provided by the water authorities were based on older (and potentially less precise) methods, combined with estimated dates when water treatments were introduced. However, these data were provided by experts blind to whether the named communities hosted cases or controls.

Information on residences over the lifetime of participants, which was used to identify residences where water sources were available for sampling or to link past residences with historical iAs measurement data, was complete for most of the participants' life-years (80%). The reconstruction of historic exposure to iAs in drinking water can therefore be considered adequate for production of exposure assessment estimates and provides a more complete characterization of overall exposure than from current sources alone ([@r18]).

Most of the ASHRAM study population was using drinking water with low iAs concentrations (75% \< 14 μg/L), well below concentrations in studies upon which the current drinking water standard is based. The use of individual measurements of iAs in drinking water for exposure estimation was validated by comparing the concentrations of iAs in the currently used water with the concentrations of iAs metabolites in urine, which is considered a good indicator of ongoing exposure ([@r29]). The concentrations of iAs in urine were significantly correlated with those in water (*R*^2^ = 0.46; *p* \< 0.001).

Several potential confounders were measured and included in the analyses and had minimal effect. However, incomplete adjustment for confounders remains a possibility.

We estimated the iAs effect when the analyses were restricted to the subgroup with sum of iAs metabolites ≥ 2.5 μg/L, based on the assumption that the relative contribution of food iAs intake to overall exposure is relatively low in this group. We found that associations between BCC and iAs exposure via water were very similar between this subgroup and the overall study population.

The possibility that exposure to low concentrations of iAs may be associated with BCC has been debated ([@r3]; [@r38]). To exclude the possibility that the association between BCC and iAs was mainly due to the few cases using water with relatively high iAs concentration, we repeated the analyses after excluding cases and controls with an average iAs concentration at or above the 90th percentile of 40.7 μg/L. Associations within this subgroup were similar to, or somewhat stronger than, those for the overall study population, which suggests that if there is a threshold for iAs effects, it may be below an iAs lifetime average concentration of 40.7 μg/L. There is increasing evidence based on mechanistic research that very low concentrations of iAs induce cell proliferation, telomerase expression, increased telomere length, and oncogene overexpression, whereas higher concentrations induce apoptosis, telomerase inhibition, and decreased telomere length ([@r15]; [@r22]; [@r32]; [@r49]). There is additional mechanistic support for effects of iAs at very low dose levels, for example, via epigenetic and endocrine interactions ([@r1]; [@r11]; [@r39]), as well as inhibition of DNA repair ([@r35]). DNA repair genes may influence individual susceptibility to BCC ([@r43]), and their role in iAs-related cancer also needs further investigation. In view of these possibilities, the overall pattern of iAs carcinogenic effects at low concentrations and possible mechanisms for low-dose effects need further study.

The pattern of risk in subgroups defined on the basis of iAs metabolism (DMA% and MA%) is broadly consistent with those of recent studies ([@r8]; [@r20]; [@r56]) and suggests increasing risk of iAs-related skin cancer with increasing percentage of MA in urine. Most of the populations previously studied experienced relatively high exposures, at which iAs methylation is inhibited, resulting in an increased percentage of urinary MA ([@r30]; [@r48]). Our findings suggest that the influence of metabolism is still present at fairly low iAs exposure levels, where iAs metabolism is mainly influenced by genetic predisposition ([@r30]). Possibly, MA in urine reflects the tissue levels of MA(III), a highly toxic intermediate metabolite ([@r12]; [@r26]).

Conclusions
===========

We found positive associations between long-term exposure to iAs \< 100 μg/L in drinking water and BCC of the skin. The exposure metric that showed the most significant relationship with BCC was lifetime average water iAs concentration. The association between iAs and BCC remained significant in the subgroup exposed to iAs lifetime average water iAs concentration \< 40 μg/L (90th percentile). Arsenic metabolism modified the risk of BCC such that the association with iAs appeared to be limited to participants with reduced iAs methylation efficiency, reflected in low DMA% and high MA% in urine. Overall, our findings add to the evidence that low-dose exposure to iAs causes cancer and support current recommendations to minimize human exposure even at relatively low concentrations.
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